Vertex Pharmaceuticals

“While Vertex has been launching, I think, have a different timeframe in mind, we have a different strategy.”

Viatris positions its fast-acting meloxicam against Vertex in the non-opioid acute pain market, differentiating on pricing and physician targeting strategy.

“where we partnered with Zai and Ono for these markets as we did in IgAN.”

Vertex partnered with Ono Pharmaceutical for povatacept in membranous nephropathy (as in IgAN) in Ono's markets.

“where we partnered with Zai and Ono for these markets as we did in IgAN.”

Vertex partnered with Zai Lab for povatacept in membranous nephropathy (as in IgAN) in Zai's markets, extending their renal collaboration.

“an exclusive global license agreement with WuXi Biologics to develop and commercialize a tri-specific T cell engager for B cell–mediated autoimmune diseases.”

Vertex signed an exclusive global license with WuXi Biologics for a preclinical tri-specific T cell engager in B cell-mediated autoimmune diseases, a business-development read-through for WuXi Biologics.

“if we look at Vera data, they're already setting eGFR”

Analyst benchmarks Vertex's pove IgAN data against competitor Vera Therapeutics' eGFR results, framing the competitive bar in IgAN.

“I think that Biogen has estimated only 36,000 patients in the U.S., which seems a bit more conservative than your combined U.S. and EU number would imply?”

Analyst cites Biogen's smaller (~36,000 US patient) sizing of the primary membranous nephropathy market, where Biogen is a competitor to Vertex's pove program.

“We were certainly very happy with the Alpine acquisition last year.”

Vertex's 2024 Alpine Immune Sciences acquisition brought povetacicept, now Vertex's lead renal asset; management cites it as a template for future BD.

“Mark was also intimately involved in the diligence that led to the Alpine acquisition, which brought povetacicept to Vertex.”

Vertex's 2024 acquisition of Alpine Immune Sciences brought povetacicept into its pipeline, which is now central to Vertex's renal and autoimmune disease strategy (IgAN, myasthenia gravis, wAIHA) — validating the deal's strategic rationale a year later.

“And on ALYFTREK, there is a dispute going on between you and Royalty Pharma as to exactly what Royalty is owed.”

An analyst raised an unresolved contractual dispute between Vertex and Royalty Pharma over royalty payments owed on ALYFTREK; management called it a straightforward contractual matter with the CF Foundation, not Royalty Pharma directly.

“Included in full-year 2024 results are $4.63 billion of acquired IPR&D charges, with the vast majority resulting from the Alpine Immune Sciences acquisition.”

Vertex's 2024 acquisition of Alpine Immune Sciences (source of povetacicept) drove a large non-cash IPR&D charge and depressed full-year GAAP operating income and tax rate.

“Also included in Q4 2024 results are $88 million of acquired IPR&D expenses, including for the Orna collaboration to develop next-generation in vivo therapeutics for sickle cell disease and beta-thalassemia.”

Vertex is paying upfront IPR&D charges to collaborate with Orna Therapeutics on in vivo therapeutics for sickle cell disease and beta-thalassemia, expanding its cell/gene therapy pipeline beyond CASGEVY.